Showing 1 - 6 results of 6 for search 'Yung‐Jue Bang', query time: 0.03s Refine Results
  1. 1
    The prognostic role of soluble TGF‐beta and its dynamics in unresectable pancreatic cancer treated with chemotherapy

    The prognostic role of soluble TGF‐beta and its dynamics in unresectable pancreatic cancer treated with chemotherapy by Hyunkyung Park, Ju‐Hee Bang, Ah‐Rong Nam, Ji Eun Park, Mei Hua Jin, Yung‐Jue Bang, Do‐Youn Oh

    Published 2020-01-01
    Get full text
    Article
  2. 2
    Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index.

    Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index. by Younak Choi, Do-Youn Oh, Tae-Yong Kim, Kyung-Hun Lee, Sae-Won Han, Seock-Ah Im, Tae-You Kim, Yung-Jue Bang

    Published 2015-01-01
    Get full text
    Article
  3. 3
    Survival Outcomes According to Adjuvant Treatment and Prognostic Factors Including Host Immune Markers in Patients with Curatively Resected Ampulla of Vater Cancer.

    Survival Outcomes According to Adjuvant Treatment and Prognostic Factors Including Host Immune Markers in Patients with Curatively Resected Ampulla of Vater Cancer. by Hye Rim Ha, Do-Youn Oh, Tae-Yong Kim, KyoungBun Lee, Kyubo Kim, Kyung-Hun Lee, Sae-Won Han, Eui Kyu Chie, Jin-Young Jang, Seock-Ah Im, Tae-You Kim, Sun-Whe Kim, Yung-Jue Bang

    Published 2016-01-01
    Get full text
    Article
  4. 4
    Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first‐line platinum‐based chemotherapy: Phase 2 study results

    Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first‐line platinum‐based chemotherapy: Phase 2 study results by Fortunato Ciardiello, Yung‐Jue Bang, Andrés Cervantes, Mikhail Dvorkin, Charles D. Lopez, Jean‐Philippe Metges, Antonio Sánchez Ruiz, Mariona Calvo, Andrew H. Strickland, George Kannourakis, Kei Muro, Hisato Kawakami, Jia Wei, Christophe Borg, Zhaoyin Zhu, Neal Gupta, Robert J. Pelham, Lin Shen

    Published 2023-06-01
    Get full text
    Article
  5. 5
    INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)

    INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by... by Lyn Ley Lam, Nick Pavlakis, Kohei Shitara, Katrin M. Sjoquist, Andrew J. Martin, Sonia Yip, Yoon-Koo Kang, Yung-Jue Bang, Li-Tzong Chen, Markus Moehler, Tanios Bekaii-Saab, Thierry Alcindor, Christopher J. O’Callaghan, Niall C. Tebbutt, Wendy Hague, Howard Chan, Sun Young Rha, Keun-Wook Lee, Val Gebski, Anthony Jaworski, John Zalcberg, Timothy Price, John Simes, David Goldstein

    Published 2023-02-01
    Get full text
    Article
  6. 6
    Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types

    Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types by Jeanne Shen, Sergio Pereira, Chan-Young Ock, Yung-Jue Bang, Seulki Kim, Sehhoon Park, Se-Hoon Lee, George A Fisher, Young Kwang Chae, Yoon-La Choi, Jin-Haeng Chung, Tony S K Mok, Leeseul Kim, Jun-Eul Hwang, Gahee Park, Sanghoon Song, Seunghwan Shin, Yoojoo Lim, Wonkyung Jung, Heon Song, Hyojin Kim, Taebum Lee, Sukjun Kim, Chang Ho Ahn, Seokhwi Kim, Ben W Dulken, Stephanie Bogdan, Maggie Huang, Chiyoon Oum, Siraj M. Ali

    Published 2024-02-01
    Get full text
    Article

Search Tools: